FibroBiologics, Inc. filings document the regulatory record of a clinical-stage biotechnology issuer developing fibroblast-based therapies. Recent disclosures cover registered equity financing through an at-the-market common stock program, shelf registration mechanics, common stock and warrant-related capital structure matters, and corporate uses of proceeds for working capital and general corporate purposes.
The company’s SEC filings also record governance and public-company administration, including annual meeting proxy proposals, director election and auditor ratification matters, stock-plan option grants to executive officers, Nasdaq continued-listing compliance, amendments to stockholder-meeting quorum provisions, and material agreements affecting its operating footprint.
FibroBiologics, Inc. entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC allowing it to sell shares of common stock with an aggregate offering price of up to $6,150,000 from time to time. Any net proceeds are expected to be used for working capital and general corporate purposes.
The Sales Agent will conduct sales as at-the-market offerings under an existing shelf registration statement on Form S-3 and a related prospectus supplement. FibroBiologics will pay a 3.0% commission on gross proceeds and reimburse specified legal and due diligence expenses. The company is not obligated to sell any shares and the ATM program can end once all authorized shares are sold or the agreement is terminated.
FibroBiologics, Inc. (FBLG) reported another quarterly loss as it funds multiple fibroblast-based cell therapy programs. For the three months ended March 31, 2026, the company recorded a net loss of $5.0 million, similar to the prior year period, as operating expenses rose to $5.1 million. Research and development spending increased to $3.0 million, reflecting preparation for clinical trials, while general and administrative costs declined to $2.1 million.
Cash and cash equivalents fell to $1.5 million as of March 31, 2026, from $4.9 million at year-end, and management disclosed “substantial doubt” about the company’s ability to continue as a going concern without additional capital. To help fund operations, FibroBiologics used its standby equity purchase agreement to sell 133,108 shares for about $0.7 million in March and later completed an April registered offering that raised approximately $2.5 million net.
The company executed a 1-for-20 reverse stock split on March 30, 2026, leaving 5,208,915 common shares outstanding as of April 30, 2026. FibroBiologics continues to advance several programs, including CYWC628 for diabetic foot ulcers, CYPS317 for psoriasis, CYMS101 for multiple sclerosis, and CybroCell™ for degenerative disc disease, but it has not yet generated revenue. Management also reported a material weakness in internal control over financial reporting related to segregation of duties and plans to add accounting staff and strengthen controls.
FibroBiologics, Inc. (FBLG) reported another quarterly loss as it funds multiple fibroblast-based cell therapy programs. For the three months ended March 31, 2026, the company recorded a net loss of $5.0 million, similar to the prior year period, as operating expenses rose to $5.1 million. Research and development spending increased to $3.0 million, reflecting preparation for clinical trials, while general and administrative costs declined to $2.1 million.
Cash and cash equivalents fell to $1.5 million as of March 31, 2026, from $4.9 million at year-end, and management disclosed “substantial doubt” about the company’s ability to continue as a going concern without additional capital. To help fund operations, FibroBiologics used its standby equity purchase agreement to sell 133,108 shares for about $0.7 million in March and later completed an April registered offering that raised approximately $2.5 million net.
The company executed a 1-for-20 reverse stock split on March 30, 2026, leaving 5,208,915 common shares outstanding as of April 30, 2026. FibroBiologics continues to advance several programs, including CYWC628 for diabetic foot ulcers, CYPS317 for psoriasis, CYMS101 for multiple sclerosis, and CybroCell™ for degenerative disc disease, but it has not yet generated revenue. Management also reported a material weakness in internal control over financial reporting related to segregation of duties and plans to add accounting staff and strengthen controls.
FibroBiologics, Inc. is soliciting votes at its virtual Annual Meeting on June 22, 2026 on director elections, auditor ratification, Nasdaq approval for certain March 2026 warrant issuances, and adoption of a new 2026 Equity and Incentive Compensation Plan. The board recommends FOR on all proposals and discloses that 125 shares of Series C Preferred Stock (held by the CEO) carry super‑voting rights totaling 1,625,000 votes the board will cast via an irrevocable proxy. The proxy materials state there were 5,208,915 shares of common stock outstanding as of April 24, 2026. The March Offering included warrants that could convert into up to 2,272,728 shares (exercise price $1.32) and placement agent warrants for up to 159,091 shares (exercise price $1.65), for which shareholder approval under Nasdaq Rule 5635(d) is being requested.
FibroBiologics, Inc. has received formal confirmation from Nasdaq that it now meets all requirements for continued listing on The Nasdaq Capital Market. Nasdaq verified compliance with both the $2.5 million stockholders’ equity requirement and the $1.00 bid price requirement, closing the previously disclosed listing matter.
The company’s common stock will continue trading under the symbol FBLG, but Nasdaq will apply one-year Mandatory Panel Monitor periods for both equity and bid price tests. If FibroBiologics falls out of compliance during these periods, Nasdaq staff would move directly to a delisting determination, though the company could request a new hearing to temporarily stay any delisting action.
FibroBiologics, Inc. reports that its board of directors approved an amendment and restatement of the company’s Bylaws on April 16, 2026. The change revises Section 2.07 to lower the quorum requirement for stockholder meetings from a majority of the voting power to one-third of the voting power.
The revised section keeps existing provisions that allow the meeting chair or stockholders present to adjourn meetings if a quorum is not reached and confirms that once a quorum is established, it is not lost by subsequent withdrawal of votes. The company filed its Second Amended and Restated Bylaws as an exhibit.
FibroBiologics, Inc. filed an amended current report to correct an omitted item number, without changing any prior disclosures. The company highlights a Sublease Buyout Agreement that ended its Webster, Texas sublease effective April 2, 2026, ahead of the original November 30, 2027 expiration.
FibroBiologics resolved all remaining rent obligations with a single payment of $45,108.25 and expects to save approximately $0.8 million in future rent. This move follows the 2025 opening of a new laboratory facility with over 10,000 square feet of lab and office space and supports consolidating operations. The company also updates its principal executive office address to 9350 Kirby Drive, Suite 300, Houston, Texas 77054.
FibroBiologics, Inc. Schedule 13G shows Lind Global Fund III LP and related reporting persons beneficially own 230,234 shares, representing 4.99% of common stock. The filing explains the position reflects 157,956 shares plus 540,536 warrants whose conversion is contractually limited to avoid ownership above 4.99%.
FibroBiologics, Inc. terminated its sublease for office space in Webster, Texas through a Sublease Buyout Agreement effective April 2, 2026, well before the original November 30, 2027 end date. The company made a single payment of $45,108.25 and expects to save approximately $0.8 million in future rent.
The change follows FibroBiologics’ 2025 opening of a new state-of-the-art laboratory facility with over 10,000 square feet of lab and office space and supports its consolidation of operations. The company’s principal executive offices are now located at 9350 Kirby Drive, Suite 300, Houston, Texas 77054.
FibroBiologics, Inc. approved a capital change by implementing a one-for-twenty reverse stock split of its common stock. The Certificate of Amendment became effective at 12:01 a.m. Eastern Time on March 30, 2026, converting every 20 issued and outstanding common shares into 1 share.
No fractional shares will be issued; any fractional share will be rounded up to the nearest whole share. The reverse split proportionately adjusts shares available under the equity incentive plan and existing options and warrants, but does not change the common stock’s par value, authorized share count, or the Nasdaq trading symbol FBLG.
FibroBiologics, Inc. completed a best-efforts public offering of 2,272,728 shares of common stock or equivalents and accompanying warrants, raising approximately $3 million in gross proceeds at a combined price of $1.32 per share and warrant. Net proceeds were about $2.5 million after fees, and are earmarked for working capital and general corporate purposes.
Investors also received warrants to purchase up to 2,272,728 additional shares at $1.32 per share, exercisable only after stockholder approval and expiring five years after that approval. If fully exercised for cash, these warrants could provide roughly $3 million in additional gross proceeds. Pre-funded warrants, issued at $1.31999 with a $0.00001 exercise price, are immediately exercisable and do not expire, subject to 9.99% beneficial ownership limits, while the other warrants and placement agent warrants carry a 4.99% ownership cap.